]]> Vaccines are the most effective way to end the Covid-19 pandemic. Credit: Shutterstock.
Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.
In the six months or so since the Covid-19 pandemic broke out in Wuhan, China, the pharma industry and university researchers from across the world have thrown themselves head-first into developing vaccines.
As of 7 July, there are 139 pre-clinical candidates and 21 clinical vaccines in development against SARS-CoV-2, the virus which causes Covid-19, according to the World Health Organization (WHO).
Of the 21 Covid-19 vaccines in clinical trials, lead candidates include Chinese biotech Sinovacs CoronaVac and the University of Oxford and AstraZenecas ChAdOx1-S both of these are in Phase III development.
Other promising candidates in Phase II trials include US-based Modernas mRNA-1273, which is being supported by the National Institute of Allergy and Infectious Diseases (NIAID), and BioNTech and Pfizers Project Lightspeed BNT162 vaccine programme.
The speed at which these companies and researchers have been able to move into and through clinical development is completely unprecedented; milestones normally achieved in years, if not decades, have been surpassed in only months.
Time is of the essence since immunity conferred through vaccines is the primary way that the world can control the spread of this deadly viral disease in the long-term, enabling the world to get back to normal.
Without taking away from this incredible achievement of science, which has been enabled by previously unseen partnerships across industry, academia and the public sector, there are already some concerns about how effective these speedily developed vaccines will be, particularly in conferring long-term immunity.
This worry has been expressed by Dr Anthony Fauci, director of NIAID and the US Governments chief health advisor; in an interview with JAMA cited by CNBC, Fauci stated that, based on previous experience with developing vaccines for other coronaviruses, its likely [the vaccine] isnt going to be a long duration of immunity.
This is also linked to that fact that most of the candidates for which there is publicly available data are focusing on inducing neutralising antibodies against SARS-CoV-2s spike protein, as noted by Nature. As a result, STAT reports it is possible that although vaccines will reduce the risk of someone contracting the disease or experiencing severe symptoms if someone is infected, they will not prevent infection entirely.
Dr Patrick Soon-Shiong, CEO and chairman of sister biotechs ImmunityBio and NantKwest, noticed this problem and his team began looking at developing a so-called second-generation Covid-19 vaccine that overcomes the short-term duration challenge of the first set of vaccines.
To this end, ImmunityBio and NantKwest are working on a Covid-19 vaccine that does not only focus on the spike protein; their vaccine also works against SARS-CoV-2s nucleocapsid.
It is our fervent belief that you cant just kill this virus from the outside in, youve got to kill it from the inside out, explains Soon-Shiong. We have created the unique construct of both nucleocapsid and spike, so that you have not just antibody, but also a memory T cell [response].
The nucleocapsid is viewed as a particularly strong stimulator of cellular immunity and improves the generation of memory T cells, explains NantKwest director of cell-mediated therapies in virology Jeffrey Safrit. T cell mediated immunity, he adds, has been shown to last significantly longer than antibody-mediated immunity.
Allowing a broader immune response involving antibody and cell-mediated immunity that is directed against more than one target lessens the ability of the virus to escape, concludes Safrit.
Another benefit of focusing on both the spike protein and nucleocapsid is linked to potential future mutations of the SARS-CoV-2 virus. Focusing on spike alone will limit vaccine effectiveness should spike mutate to avoid the immune response, explains Safrit.
Whereas the nucleocapsid gene is highly conserved among coronaviruses, meaning it mutates much less often if at all, therefore, Safrit notes, inclusion of nucleocapsid makes our approach a more universal Covid vaccine, that could even be useful against related future, yet unseen SARS infections.
Soon-Shiong was also concerned about how many leading Covid-19 candidates, such as the University of Oxford/AstraZeneca project, are relying on the adenovirus approach.
Current adenovirus vaccines are based on the first generation of this vector [Ad5] that generate significant anti-vector immunity when administered which can dampen or the even negate the immune response [conferred by the vaccine] to the Covid-19 spike protein and nucleocapsid, explains Safrit. This situation is worsened when someone has been previously exposed to an adenovirus, such as that which causes the common cold.
To overcome this challenge, NantKwest and ImmunityBio have developed a second-generation Ad5 platform. It has demonstrated safety in Phase I and II studies in cancer patients. The companies also carried out a successful proof-of-concept during the 2009 H1N1 influenza pandemic.
The platform has additional deletions of adenovirus genes that generate little to no vector-specific immunity and focuses the immune response on the inserted genes of interest, SARS-CoV-2 spike protein and nucleocapsid, says Safrit.
Because of this, the second-generation Ad5 also overcomes any adenovirus pre-existing immunity, allowing a more effective first vaccination and multiple subsequent booster vaccinations without reduced immunogenicity, he explains.
Soon-Shiong is clear that long-term duration of immunity challenges will be solved by second-generation vaccines such as Immunity Bio and NantKwests candidate.
Their vaccine, which is part of the US Governments Operation Warp Speed, is ready to launch into Phase I clinical trials this summer with early safety and preliminary efficacy results expected before the end of the year.
However, there is a need for further innovations so that the vaccine can be administered without injections to overcome access challenges, particularly in developing countries.
If we could achieve an oral form, which is not unrealistic, that would be the third generation Covid-19 vaccine, Soon-Shiong notes.
This is an avenue that ImmunityBio and NantKwest are pursuing for their Covid-19 vaccine candidate, but it is currently early in development, according to Soon-Shiong. Their oral capsule approach would avoid significant cold chain requirements of all current vaccine approaches, Safrit states.
It would also introduce the prospect of conferring mucosal immunity, generation [of] which could significantly improve the ability of the vaccine to protect against infection and disease.
Other companies slightly further along with their oral vaccines include the UKs Stabilitech and US-based Vaxart.
Stabilitechs OraPro-COVID-19, which is developed using its proprietary OraPro technology platform, aims to confer both mucosal and systemic immunity to patients in a thermally stable way. Clinical trials for this vaccine are expected to begin in August this year.
The company has recently completed a fundraising round and signed a manufacturing agreement with BioCell Corporation in New Zealand. Talking about this news, Stabilitech chairman Wayne Channon stated: It brings us closer to providing a vaccine that gives both mucosal and systemic immunity to Covid-19.
This will target the virus exactly where we catch it: in the mucous membranes of the mouth, nose, throat and even the eyes.
By taking this approach, we believe OraPro-COVID-19 could prove to provide the fastest route to widespread global immunity, turning the tide on the pandemic.
Vaxarts oral vaccine approach relies on its VAAST delivery platform. It delivers two payloads to cells in the small bowel epithelium; the second of the payloads acts like an adjuvant to further activate the immune system against the selected viral antigen.
Like ImmunityBio and NantKwests candidate, Vaxarts oral approach is one of the projects chosen to be part of the US Governments Operation Warp Speed. Following on from positive pre-clinical results in April, Vaxarts candidate is on track to move into clinical studies this summer.
Talking about this announcement, Vaxart CEO Andrei Floroiu said: We are very pleased to be one of the few companies selected by Operation Warp Speed, and that ours is the only oral vaccine being evaluated.
SARS-CoV-2, the coronavirus that causes COVID-19, is primarily transmitted by viral particles that enter through the mucosa nose, mouth or eyes strongly suggesting that mucosal immunity could serve as the first line of defence.
In addition, our vaccine is a room temperature-stable tablet, an enormous logistical advantage in large vaccination campaigns.
Read the original here:
Gene therapy innovations: Sarepta and Codiak partner on exosomes - Pharmaceutical Technology
- IOM not webcast today. Why Not? [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- National Academies skeptical at Best. [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Some Confusion Exists [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Why DTC Genomics IS Medicine. [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- First Mari, Now Linda. Who's next? [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Is it true? [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Re-Reviewing the National Academies [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- The problem with nonclinicians....... [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Crazy Night of Emails to Government [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Adrienne Carlson's Personalized Medicine. [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Tell Me, How do you feel now? Sherpa's RX [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- This Just In. 23andMe to go to GPs. I love my readers!! [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Sorry so long away [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- 2D6 Rears its ugly head..... [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Ok, Fine, Back to Plavix [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Kaiser a protoype for Collins' Aim [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- A few months late to the party.... [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Stated Another Way....... [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Excuse Me? Harvard and Navigenics? WTF? [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Follow up to Yesterday's WTF? Harvard, Navi? and Pfizer??? [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Did you get your kit? Thanks Dr. Rob from MedCo [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Gluco...Wha? Parkinson's Disease and Glucocerebrosidase mutations. [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Away and now back, What did I miss???? 23andme layoffs? Selling Genomes for cheap up next! [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Change IS Needed. I agree with William, sometimes. [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Good Enough Science? Apparently so at 23andme [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Long QT Syndrome, location matters [Last Updated On: December 13th, 2009] [Originally Added On: December 13th, 2009]
- Congratulations Generation Health. Nice pick up! [Last Updated On: December 13th, 2009] [Originally Added On: December 13th, 2009]
- An argument 23andSerge can't win...23andme but not medicine [Last Updated On: December 13th, 2009] [Originally Added On: December 13th, 2009]
- Stop. Breathe. Repeat. An analysis of the direction of DTC Genomics Field. [Last Updated On: December 13th, 2009] [Originally Added On: December 13th, 2009]
- Hey DTC genomics, Stay Private, Stay Alive, Go Public and Die [Last Updated On: December 13th, 2009] [Originally Added On: December 13th, 2009]
- You can't have it both way. Either scared your genome is sold off or not. [Last Updated On: December 13th, 2009] [Originally Added On: December 13th, 2009]
- 15 Days Away Gives Time for Perspective. [Last Updated On: December 13th, 2009] [Originally Added On: December 13th, 2009]
- What about the SACGHS registry? Another missed opportunity? [Last Updated On: December 13th, 2009] [Originally Added On: December 13th, 2009]
- AJHG is in and my Favorite Muin is in it! But He Is NOT the Father! [Last Updated On: December 13th, 2009] [Originally Added On: December 13th, 2009]
- Navigenics for 23andMe prices? [Last Updated On: December 18th, 2009] [Originally Added On: December 18th, 2009]
- Lp(a) Maybe there's something there that wasn't there before? [Last Updated On: December 24th, 2009] [Originally Added On: December 24th, 2009]
- Another Year, Another Bankruptcy [Last Updated On: December 31st, 2009] [Originally Added On: December 31st, 2009]
- 5 Technologies going bye bye in this decade? [Last Updated On: January 6th, 2010] [Originally Added On: January 6th, 2010]
- Hackers, HITECH and HIPAA in DTC Genomics, Oh My! [Last Updated On: January 7th, 2010] [Originally Added On: January 7th, 2010]
- Personal Genomics Flop.....big Belly Flop! [Last Updated On: January 8th, 2010] [Originally Added On: January 8th, 2010]
- Gotta Love It. Even the daycare....... [Last Updated On: January 11th, 2010] [Originally Added On: January 11th, 2010]
- Congratulations Navigenics. You ARE a clinical lab! Uh-Oh... [Last Updated On: January 12th, 2010] [Originally Added On: January 12th, 2010]
- CETP, Jewish Centenarians and Alzheimers [Last Updated On: January 14th, 2010] [Originally Added On: January 14th, 2010]
- Enter the "Not" DTC Genomics Rep [Last Updated On: January 17th, 2010] [Originally Added On: January 17th, 2010]
- Why Dr. Vanier's Navigenics appointment is good for PM [Last Updated On: January 22nd, 2010] [Originally Added On: January 22nd, 2010]
- Holy Crap! MedCo Follows in CVS footsteps [Last Updated On: February 3rd, 2010] [Originally Added On: February 3rd, 2010]
- FDA, Warfarin, still not as sexy to me. [Last Updated On: February 5th, 2010] [Originally Added On: February 5th, 2010]
- Hype, Hype, Hype from a single study. [Last Updated On: February 11th, 2010] [Originally Added On: February 11th, 2010]
- I love my readers, even Renata M! [Last Updated On: February 17th, 2010] [Originally Added On: February 17th, 2010]
- How can insurers use DTC genomics to profile? [Last Updated On: February 17th, 2010] [Originally Added On: February 17th, 2010]
- 9p21.....ahem. Paynter et.al. Smackdown. Again. [Last Updated On: February 18th, 2010] [Originally Added On: February 18th, 2010]
- Hey! It's Pete Hulick! Are you Going to GET? [Last Updated On: February 19th, 2010] [Originally Added On: February 19th, 2010]
- I was wrong......AHEM [Last Updated On: February 28th, 2010] [Originally Added On: February 28th, 2010]
- G2C2, finally a tool for genomic education! [Last Updated On: March 2nd, 2010] [Originally Added On: March 2nd, 2010]
- Just 4 million? What 23andMe is worth. [Last Updated On: March 5th, 2010] [Originally Added On: March 5th, 2010]
- What a difference a year makes [Last Updated On: March 9th, 2010] [Originally Added On: March 9th, 2010]
- ........DTC Genomic Medicine? [Last Updated On: March 12th, 2010] [Originally Added On: March 12th, 2010]
- The FDA, 2c19 and the ACC [Last Updated On: March 13th, 2010] [Originally Added On: March 13th, 2010]
- The problem with Comparative Whole Genomics...... [Last Updated On: March 13th, 2010] [Originally Added On: March 13th, 2010]
- BRCA testing by 23andME is the same as Myriad Genetics. [Last Updated On: March 15th, 2010] [Originally Added On: March 15th, 2010]
- The Argument Against DTC Genomics Marketing and such [Last Updated On: March 16th, 2010] [Originally Added On: March 16th, 2010]
- A moment of Clarity. Some DTCG is not bad. [Last Updated On: March 18th, 2010] [Originally Added On: March 18th, 2010]
- SNPs for breast cancer risk? It Depends. [Last Updated On: March 18th, 2010] [Originally Added On: March 18th, 2010]
- How can MDVIP use Navigenics Test for Medicine? [Last Updated On: March 18th, 2010] [Originally Added On: March 18th, 2010]
- Why did P&G invest in Navigenics? [Last Updated On: March 23rd, 2010] [Originally Added On: March 23rd, 2010]
- PGx in DTCG? Doesn't stand up to Useful testing. [Last Updated On: March 25th, 2010] [Originally Added On: March 25th, 2010]
- End of Gene Patents? [Last Updated On: March 29th, 2010] [Originally Added On: March 29th, 2010]
- Sherpa Accepting Chief Medical Officership [Last Updated On: April 3rd, 2010] [Originally Added On: April 3rd, 2010]
- The Rumors of My Death........ [Last Updated On: April 20th, 2010] [Originally Added On: April 20th, 2010]
- Happy DNA Day! [Last Updated On: April 25th, 2010] [Originally Added On: April 25th, 2010]
- 99 USD, DNA day and patient letters [Last Updated On: April 25th, 2010] [Originally Added On: April 25th, 2010]
- 2C19, Navigenics and Clinical Reality. [Last Updated On: May 1st, 2010] [Originally Added On: May 1st, 2010]
- Coriell Personalized Medicine Collaborative rising [Last Updated On: May 7th, 2010] [Originally Added On: May 7th, 2010]
- Personal Genomes in Clinical Care. Quake paper is a waste! [Last Updated On: May 11th, 2010] [Originally Added On: May 11th, 2010]
- Personal Genomes in Clinical Care. Quake paper Falls Short! [Last Updated On: May 13th, 2010] [Originally Added On: May 13th, 2010]
- Last post edited by Drew [Last Updated On: May 13th, 2010] [Originally Added On: May 13th, 2010]
- GateKeeper? FCUK U! [Last Updated On: May 13th, 2010] [Originally Added On: May 13th, 2010]
- GateKeeper? F! U! [Last Updated On: May 15th, 2010] [Originally Added On: May 15th, 2010]
- Potential of genomic medicine, LOST [Last Updated On: May 19th, 2010] [Originally Added On: May 19th, 2010]
- How Bad Can a House Investigation be for DTC Genomics? [Last Updated On: May 20th, 2010] [Originally Added On: May 20th, 2010]